ストックスクリーナーアプリを入手
0.3536
4.77%
-0.0177
前日終値:
$0.3713
開ける：
$0.3607
24時間の取引高:
340.82K
Relative Volume:
0.25
時価総額：
$2.20M
収益：
-
当期純損益:
$-22.56M
株価収益率:
-0.1832
EPS:
-1.93
ネットキャッシュフロー:
$-16.12M
1週間 パフォーマンス:
-10.10%
1か月 パフォーマンス:
-73.21%
6か月 パフォーマンス:
-84.29%
1年 パフォーマンス:
+30.47%
1日の値動き範囲:
$0.3241
$0.377
1週間の範囲:
$0.3241
$0.3933
52週間の値動き範囲:
$0.231
$4.3785
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
名前
Cyclacel Pharmaceuticals Inc
セクター
電話
908-517-7330
住所
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
CYCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CYCC | 0.3585 | 2.20M | 0 | -22.56M | -16.12M | -1.93 |
| VRTX | 449.11 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.63 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.08 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.44 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.09 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2020-04-27 | 再開されました | ROTH Capital | Buy |
| 2018-09-07 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-10-16 | 開始されました | H.C. Wainwright | Buy |
| 2010-02-04 | 開始されました | Roth Capital | Buy |
| 2009-10-28 | 開始されました | Merriman | Buy |
| 2008-08-12 | 開始されました | Piper Jaffray | Buy |
| 2008-03-12 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2008-03-12 | 繰り返されました | Collins Stewart | Buy |
| 2008-03-12 | 繰り返されました | Needham & Co | Buy |
| 2007-11-27 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2007-08-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2007-06-04 | 繰り返されました | Needham & Co | Buy |
| 2007-04-23 | 開始されました | Lazard Capital | Buy |
| 2007-04-10 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Cyclacel Pharmaceuticals Inc (CYCC) 最新ニュース
Cyclacel stock plunges to 52-week low of $0.32 amid market challenges - Investing.com
Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Armistice Capital, LLC Increases Stake in Cyclacel Pharmaceutica - GuruFocus.com
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss - MSN
Cyclacel stock plunges to 52-week low of $0.37 amid market challenges - Investing.com Canada
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise Deal at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals appoints new auditor By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals appoints new auditor - Investing.com India
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Faces Delisting Risk Despite 67% Lower Q3 Loss; Cash Concerns Mount | CYCC Stock News - StockTitan
(CYCCP) Technical Pivots with Risk Controls - Stock Traders Daily
A Data-Based Look At Cyclacel Pharmaceuticals Inc (CYCC) - Stocks Register
Cyclacel stock plunges to 52-week low at $0.6 amid market challenges - Investing.com
Cyclacel stock plunges to 52-week low at $0.74 amid market challenges - Investing.com India
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - The Manila Times
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - ForexTV.com
Nasopharyngeal Cancer Market Report: Growth Forecast and Key - openPR
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
CYCCPCyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94 - MSN
Cyclacel stock plunges to 52-week low, touches $0.8 By Investing.com - Investing.com Australia
Cyclacel stock plunges to 52-week low, touches $0.8 - Investing.com
CYCCCyclacel Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - The Manila Times
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - ForexTV.com
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
(CYCCP) Trading Report - Stock Traders Daily
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Cyclacel halts dividend on preferred stock - Investing.com
Cyclacel halts dividend on preferred stock By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - ForexTV.com
Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Benzinga
Cyclacel Pharmaceuticals Inc (CYCC) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):